Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors — Tamar Tadmor (2024) | RDL Network
Improved Survival of Patients With Chronic Lymphocytic Leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors
Anticancer Research 44(5): 2109-2115
Article 2024 English
Authors
TT
Tamar Tadmor
GM
Guy Melamed
HA
Hilel Alapi
Abstract
1 min read
The treatment for chronic lymphocytic leukemia (CLL) has changed dramatically over the last two decades. The current study aimed to investigate the impact on overall survival (OS) and time to next treatment (TTT) among CLL patients from 1998 to 2022.
Jan A. Burger, Kelvin W. Li, Michael J. Keating, Mariela Sivina, Ahmed M. Amer, Naveen Garg, Alessandra Ferrajoli, Xuelin Huang, Hagop Kantarjian, William G. Wierda, Susan O’Brien, Marc Hellerstein, Scott Turner, Claire Emson, Shih‐Shih Chen, Xiao‐Jie Yan, Dominik Wodarz, Nicholas Chiorazzi
Discussion(0)
No comments yet. Be the first to comment.